SCHEMBL3512048

SCHEMBL3512048

CC(C)(C)OC(=O)c1ccc(N2CCOCC2)cc1N

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKDC P78527 4/20 0.51
LGMN Q99538 4/20 0.50
PIK3CD O00329 2/20 0.44
PIK3CA P42336 2/20 0.44
PIK3CB P42338 2/20 0.44
PIK3CG P48736 2/20 0.44
MAPT P10636 5/20 0.44
USP30 Q70CQ3 1/20 0.44
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 2/20 0.44
HTT P42858 1/20 0.44
TDP1 Q9NUW8 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
GPR119 Q8TDV5 1/20 0.43
HIF1A Q16665 1/20 0.42
KMO O15229 1/20 0.41
LMNA P02545 1/20 0.41
HDAC3 O15379 1/20 0.41
HDAC4 P56524 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27785054 0.88 PRKDC (0.49) PRKDCLGMNPIK3CDPIK3CAPIK3CB
SCHEMBL589358 0.86 KDM4E (0.51) MAPTKDM4EALDH1A1HTTKMT2A
SCHEMBL5054798 0.85 PRKDC (0.55) PRKDCLGMNPIK3CDPIK3CAPIK3CB
SCHEMBL2089435 0.85 PRKDC (0.51) PRKDCPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL3514309 0.85 MAPT (0.47) MAPTALDH1A1HTT
SCHEMBL26270122 0.84 GFER (0.52) MAPTKDM4EALDH1A1HTTTDP1
SCHEMBL21430925 0.82 LGMN (0.57) PRKDCLGMNPIK3CAMAPTKDM4E
SCHEMBL3510961 0.81 PDK2 (0.43) MAPTALDH1A1HTTTDP1GPR119
SCHEMBL3513419 0.81 MAPT (0.47) MAPTKDM4EALDH1A1HTTKMT2A
SCHEMBL30590429 0.81 PRKDC (0.71) PRKDCLGMNPIK3CDPIK3CAPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220144813-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2022-05-12 US disclosed
US-20200377487-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2020-12-03 US disclosed
US-20190241546-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2019-08-08 US disclosed
US-10081622-B2 Substituted indazole derivatives active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2018-09-25 US disclosed
US-20170158677-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2017-06-08 US disclosed
US-9616059-B2 Substituted indazole derivatives active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2017-04-11 US disclosed
EP-2176231-B1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2016-10-19 EP disclosed
EP-2547664-B1 MORPHOLINYLQUINAZOLINES MERCK PATENT GMBH (DE) 2016-05-04 EP disclosed
US-20160095856-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2016-04-07 US disclosed
US-9255087-B2 Substituted indazole derivatives active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2016-02-09 US disclosed
US-20130018036-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-01-17 US disclosed
US-20130012489-A1 Morpholinylquinazolines MERCK PATENT GMBH (DE) 2013-01-10 US disclosed
US-20130012489-A1 Morpholinylquinazolines MERCK PATENT GMBH (DE) 2013-01-10 US disclosed
US-20130012489-A1 Morpholinylquinazolines MERCK PATENT GMBH (DE) 2013-01-10 US disclosed
CN-102803227-A Morpholinyl quinazolines MERCK PATENT GMBH 2012-11-28 CN disclosed
US-8299057-B2 Substituted indazole derivatives active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-10-30 US disclosed
WO-2011113512-A1 MORPHOLINYLQUINAZOLINES MERCK PATENT GMBH (DE) 2011-09-22 WO disclosed
US-20100292207-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2010-11-18 US disclosed
EP-2176231-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Nerviano Medical Sciences S.r.l. (IT) 2010-04-21 EP disclosed
WO-2009013126-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10081622-B2 Substituted indazole derivatives active as kinase inhibitors MAP3K19, ABL1, MAP3K20 PRKDC 44/4885LGMN 4560/4885PIK3CD 222/4885
US-20100292207-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS MAP3K19, MAP3K3, MAP3K5 PRKDC 50/4885LGMN 4462/4885PIK3CD 135/4885
US-20160095856-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS MAP3K19, ABL1, MAP3K20 PRKDC 44/4885LGMN 4560/4885PIK3CD 222/4885
US-20130012489-A1 Morpholinylquinazolines LATS2, TNK2, SKP1 PRKDC 2343/4885LGMN 4860/4885PIK3CD 1763/4885
US-20200377487-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS MAP3K19, ABL1, MAP3K20 PRKDC 44/4885LGMN 4560/4885PIK3CD 222/4885
US-20190241546-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS MAP3K19, ABL1, MAP3K20 PRKDC 44/4885LGMN 4560/4885PIK3CD 222/4885
US-20130018036-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS MAP3K19, MAP3K3, MAP3K5 PRKDC 50/4885LGMN 4462/4885PIK3CD 135/4885
US-20220144813-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS MAP3K19, ABL1, MAP3K20 PRKDC 44/4885LGMN 4560/4885PIK3CD 222/4885
US-20170158677-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS MAP3K19, ABL1, MAP3K20 PRKDC 44/4885LGMN 4560/4885PIK3CD 222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.